Alpha-7 nAChR Positive Allosteric Modulators for Cognitive and Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current alpha-7 nicotinic acetylcholine receptor (nAChR) agonists face challenges due to rapid desensitization and potential endogenous tone disruption, limiting their clinical utility, while existing positive allosteric modulators (PAMs) may not effectively address chronic and neuropathic pain models.
Innovation Solution
Development of compounds that bind to an allosteric site on the alpha-7 nAChR, acting as positive allosteric modulators with or without allosteric agonist activity, to enhance orthosteric-site-mediated signaling without direct receptor activation or desensitization, including specific structures represented by Formulas I, II, III, and IV, which are enantiomerically pure and capable of improving cognitive function, reducing inflammation, and treating pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alpha-7 nAChR agonists are used to treat neurological conditions, then cognitive function is improved, but rapid desensitization occurs limiting clinical utility
Solution Approach 1:
The patent introduces positive allosteric modulators (PAMs) as intermediary compounds that indirectly enhance alpha-7 nAChR signaling through endogenous acetylcholine rather than directly activating the receptor. These PAMs bind to allosteric sites and increase the receptor's sensitivity and response to physiological levels of acetylcholine, thereby improving cognitive function without causing the rapid desensitization associated with direct agonists. This intermediary mechanism allows for sustained therapeutic effect without the limitations of traditional agonist approaches.
2Power
If high agonist concentration is used to enhance alpha-7 nAChR signaling, then peak response is increased, but desensitization rate increases
Solution Approach 1:
The patent employs parameter changes by modifying the binding characteristics and pharmacological properties of the compounds. Instead of using high concentrations of direct agonists that cause rapid desensitization, the invention uses positive allosteric modulators with specific binding parameters that enhance receptor response to physiological acetylcholine levels. These PAMs exhibit optimized affinity and efficacy parameters that allow for sustained peak responses without accelerating desensitization, effectively changing the pharmacological parameters of receptor activation.
3Reliability
If existing PAMs are used to modulate alpha-7 nAChR, then orthosteric-site-mediated signaling is augmented, but chronic and neuropathic pain models are not effectively treated
Solution Approach 1:
The patent achieves universality by designing positive allosteric modulators with optimized pharmacological properties that effectively treat multiple therapeutic indications including cognitive disorders, chronic pain, and neuropathic pain. The disclosed PAMs exhibit broad therapeutic versatility by simultaneously addressing cognitive enhancement and pain management through their ability to modulate alpha-7 nAChR signaling in different neural circuits and pathological contexts. This multi-functional approach overcomes the limitation of existing PAMs that were primarily evaluated for cognitive effects.
Data Source
AI summary
Compounds are provided which bind to an allosteric site on the mammalian alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR) and act as positive allosteric modulators with or without allosteric agonist activity. The compounds are useful in diagnosing, preventing, or treating a variety of disorders involving cognition, learning, memory, neurodegeneration, drug addiction, inflammation, chronic pain, and neuropathic pain. The compounds also can be used to enhance memory and learning in normal individuals.